Tim Kutzkey Purchases 18,052 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey bought 18,052 shares of the stock in a transaction dated Tuesday, January 20th. The stock was purchased at an average price of $19.60 per share, with a total value of $353,819.20. Following the purchase, the director owned 1,016,658 shares in the company, valued at $19,926,496.80. This trade represents a 1.81% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Tim Kutzkey also recently made the following trade(s):

• On Friday, January 16th, Tim Kutzkey purchased 2,562 shares of Surrozen stock. The stock was bought at an average price of $20.00 per share, for a total transaction of $51,240.00.
• On Thursday, January 15th, Tim Kutzkey purchased 11,893 shares of Surrozen stock. The shares were purchased at an average price of $19.89 per share, with a total value of $236,551.77.
• On Wednesday, January 14th, Tim Kutzkey acquired 5,523 shares of Surrozen stock. The stock was bought at an average price of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 13th, Tim Kutzkey purchased 12,470 shares of Surrozen stock. The stock was bought at an average price of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Tim Kutzkey acquired 15,100 shares of Surrozen stock. The stock was bought at an average cost of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The shares were bought at an average price of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey bought 5,266 shares of Surrozen stock. The stock was purchased at an average cost of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey bought 315,457 shares of Surrozen stock. The shares were purchased at an average price of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Price Performance

SRZN opened at $19.17 on Thursday. The company has a 50 day simple moving average of $19.11 and a two-hundred day simple moving average of $14.17. The firm has a market cap of $164.29 million, a P/E ratio of -0.86 and a beta of 0.58. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $24.94.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The firm had revenue of $0.98 million for the quarter. Equities analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Institutional Trading of Surrozen

Several hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC increased its stake in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after acquiring an additional 3,424 shares during the last quarter. Geode Capital Management LLC raised its holdings in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after buying an additional 5,702 shares during the period. Acuta Capital Partners LLC lifted its position in Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after buying an additional 8,415 shares during the last quarter. Stonepine Capital Management LLC boosted its stake in Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after buying an additional 20,247 shares during the period. Finally, Vanguard Group Inc. increased its position in Surrozen by 21.7% during the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock valued at $3,433,000 after acquiring an additional 47,468 shares during the last quarter. 66.57% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Lifesci Capital raised Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Wall Street Zen raised shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Key Headlines Impacting Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Director Tim Kutzkey completed several open‑market buys on Jan 6, 13, 14, 15, 16 and 20 totaling tens of thousands of shares (~$641k reported across the most recent three purchases) and now directly owns ~1.02M shares — insider accumulation is often read as a bullish confidence vote. Surrozen (NASDAQ:SRZN) Director Purchases $51,240.00 in Stock
• Positive Sentiment: Major shareholder Group GP LP Column III mirrored the insider purchases (Jan 15, 16 and 20), increasing its stake by ~1.2–1.8% per disclosed tranche to ~1.02M shares — coordinated buying by a large holder reinforces the positive insider signal. Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Acquires 2,562 Shares
• Neutral Sentiment: The disclosures are routine SEC beneficial‑ownership filings that document the trades and updated holdings; they do not indicate corporate actions (e.g., buybacks or financings) by Surrozen itself. SEC filing — Kutzkey purchases
• Negative Sentiment: Company fundamentals remain weak: Surrozen reported a steep Q3 EPS miss (reported -$3.61 vs -$1.17 expected) and minimal revenue, leaving substantial operating losses that could cap the stock’s upside unless clinical or commercial progress materially improves. MarketBeat — SRZN profile

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.